Brief: Reata Pharmaceuticals Announces FDA Filing Acceptance And Priority Review Designation For NDA For Omaveloxolone For Treatment Of Patients With Friedreich's Ataxia
26/05/2022 11:55
May 26 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS ANNOUNCES FDA FILING ACCEPTANCE AND
PRIORITY REVIEW DESIGNATION FOR THE NDA FOR OMAVELOXOLONE FOR
THE TREATMENT OF PATIENTS WITH FRIEDREICH’S ATAXIA
* REATA PHARMACEUTICALS INC - APPLICATION ASSIGNED A PDUFA
DATE OF
NOVEMBER 30, 2022
* REATA PHARMACEUTICALS INC - FDA INDICATED IT IS CURRENTLY
PLANNING TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS
APPLICATION
Source text for Eikon: ID:nBw5n2N4Xa
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer